key: cord-1032272-uh4z9o3s
authors: Fierro, Nora A.; Torres-Flores, Jesus; Mirazo, Santiago
title: COVID-19 therapy: from lung disease to systemic disorder
date: 2022-05-08
journal: Curr Opin Pharmacol
DOI: 10.1016/j.coph.2022.102246
sha: c74c5f071cf5028ae024fe5bde628074ad3361b6
doc_id: 1032272
cord_uid: uh4z9o3s

nan

It has been suggested that peripheral inflammation triggered by SARS-CoV-2 can still be relayed to brain cells, triggering inflammation into the central nervous system (2) . Neuroinflammation and its relationship to COVID-19 is illustrated by Edda Sciutto and colleagues; the appearance of neurological sequalae as well as the recently coined term NeuroCOVID, useful for the diagnosis, management and treatment of patients are summarized. We deeply thank to all the leading experts who contributed to this special issue. Undebatably, the advances discussed open new avenues of investigation with therapeutical potential to successfully combat COVID-19 and to contain emerging virus in the future.

The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology

Single-cell transcriptomics reveals neuroinflammation in severe COVID-19